Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,929 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02117479 | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | terminated | Phase 3 | 321 | Incyte CorporationINDUSTRY | 12 | Mar 26, 2019 | clinicaltrials |
| NCT00096408 | Laparoscopic Approach to Cancer of the Endometrium | completed | Phase 3 | 760 | Queensland Centre for Gynaecological CancerOTHER_GOV | 4 | Mar 20, 2019 | clinicaltrials |
| completed |
| Phase 2 / Phase 3 |
| 326 |
| Janssen Research & Development, LLCINDUSTRY |
| 14 |
| Mar 19, 2019 |
| clinicaltrials |
| NCT01907100 | Nintedanib (BIBF 1120) in Mesothelioma | terminated | Phase 2 / Phase 3 | 545 | Boehringer IngelheimINDUSTRY | 27 | Mar 18, 2019 | clinicaltrials |
| NCT01961609 | Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.(SIGNATURE) | completed | Phase 3 | 235 | Novartis PharmaceuticalsINDUSTRY | 2 | Mar 18, 2019 | clinicaltrials |
| NCT01243944 | Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | completed | Phase 3 | 222 | Incyte CorporationINDUSTRY | 18 | Mar 6, 2019 | clinicaltrials |
| NCT01502696 | Adjuvant PEG Intron in Ulcerated Melanoma | unknown | Phase 3 | 1,200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Mar 4, 2019 | clinicaltrials |
| NCT01881230 | Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)(tnAcity) | completed | Phase 2 / Phase 3 | 191 | CelgeneINDUSTRY | 12 | Feb 21, 2019 | clinicaltrials |
| NCT00532727 | Triple Negative Breast Cancer Trial(TNT) | unknown | Phase 3 | 400 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT02409355 | A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | terminated | Phase 3 | 8 | Hoffmann-La RocheINDUSTRY | 14 | Feb 15, 2019 | clinicaltrials |
| NCT02605044 | Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer | terminated | Phase 3 | 123 | AB ScienceINDUSTRY | 3 | Feb 11, 2019 | clinicaltrials |
| NCT01020448 | Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer(Triptocare) | completed | Phase 3 | 339 | IpsenINDUSTRY | 10 | Jan 30, 2019 | clinicaltrials |
| NCT01633060 | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi(BELLE-3) | terminated | Phase 3 | 432 | Novartis PharmaceuticalsINDUSTRY | 22 | Jan 30, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | completed | Phase 3 | 326 | PfizerINDUSTRY | 20 | Jan 9, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT00867347 | Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer | completed | Phase 3 | 45 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT00876395 | Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer(BOLERO-1) | completed | Phase 3 | 719 | Novartis PharmaceuticalsINDUSTRY | 28 | Dec 19, 2018 | clinicaltrials |
| NCT00789373 | A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 15 | Dec 14, 2018 | clinicaltrials |
| NCT02785900 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia(CASCADE) | terminated | Phase 3 | 240 | Seagen Inc.INDUSTRY | 16 | Dec 12, 2018 | clinicaltrials |
| NCT00974311 | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy(AFFIRM) | completed | Phase 3 | 1,199 | PfizerINDUSTRY | 15 | Dec 11, 2018 | clinicaltrials |
| NCT00805194 | LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer | completed | Phase 3 | 1,314 | Boehringer IngelheimINDUSTRY | 27 | Dec 5, 2018 | clinicaltrials |
| NCT01668459 | Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel(CabB1) | completed | Phase 2 / Phase 3 | 20 | Dr Anjali ZarkarOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01980875 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 57 | Gilead SciencesINDUSTRY | 8 | Nov 19, 2018 | clinicaltrials |
| NCT01980888 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 311 | Gilead SciencesINDUSTRY | 13 | Nov 19, 2018 | clinicaltrials |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 | clinicaltrials |
| NCT01732926 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Bridalveil) | terminated | Phase 3 | 475 | Gilead SciencesINDUSTRY | 15 | Nov 16, 2018 | clinicaltrials |
| NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | completed | Phase 3 | 122 | Novartis PharmaceuticalsINDUSTRY | 17 | Nov 8, 2018 | clinicaltrials |
| NCT03731026 | The LightPath® and 68Ga-RM2 in Breast Cancer Study | unknown | Phase 3 | 80 | Lightpoint Medical LimitedINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00641095 | Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma(MCLPIII) | completed | Phase 2 / Phase 3 | 370 | University College, LondonOTHER | 2 | Oct 31, 2018 | clinicaltrials |
| NCT02741856 | Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation(SCOPE2) | unknown | Phase 2 / Phase 3 | 584 | Lisette NixonOTHER_GOV | 1 | Oct 25, 2018 | clinicaltrials |
| NCT00626600 | A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion | terminated | Phase 3 | 33 | Mundipharma Research LimitedINDUSTRY | 1 | Oct 24, 2018 | clinicaltrials |
| NCT00375674 | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer(S-TRAC) | completed | Phase 3 | 674 | PfizerINDUSTRY | 22 | Sep 21, 2018 | clinicaltrials |
| NCT01104571 | Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer(EPHOS-B) | unknown | Phase 3 | 257 | Institute of Cancer Research, United KingdomOTHER | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT00984282 | Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | completed | Phase 3 | 417 | BayerINDUSTRY | 18 | Sep 13, 2018 | clinicaltrials |
| NCT00332202 | PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | completed | Phase 3 | 758 | Eli Lilly and CompanyINDUSTRY | 25 | Sep 10, 2018 | clinicaltrials |
| NCT01191801 | Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML(VALOR) | completed | Phase 3 | 711 | Sunesis PharmaceuticalsINDUSTRY | 15 | Aug 22, 2018 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials